-
1
-
-
0016804136
-
A clinical staging system for multiple myeloma
-
Durie BGM and Salmon SE: A clinical staging system for multiple myeloma. Cancer 36: 842-854, 1975.
-
(1975)
Cancer
, vol.36
, pp. 842-854
-
-
Durie, B.G.M.1
Salmon, S.E.2
-
2
-
-
0025098172
-
Effect of glucocorticoids on the biologic activity of myeloma cells: Inhibition of interleukin-1β ostoclasts activating factor-induced bone resorption
-
Ishikawa H, Tanaka H, Iwato K, Tanabe O, Asaoku H, Nobuyoshi M, Yamamoto I, Kawano M and Kuramoto A: Effect of glucocorticoids on the biologic activity of myeloma cells: Inhibition of interleukin-1β ostoclasts activating factor-induced bone resorption. Blood 75: 715-720, 1990.
-
(1990)
Blood
, vol.75
, pp. 715-720
-
-
Ishikawa, H.1
Tanaka, H.2
Iwato, K.3
Tanabe, O.4
Asaoku, H.5
Nobuyoshi, M.6
Yamamoto, I.7
Kawano, M.8
Kuramoto, A.9
-
3
-
-
0037105599
-
-
Abe M, Hiura K, Wilde J, Moriyama k, Hashimoto T, Ozaki S, Wakatsuki S, Kosaka M, Kido S, Inoue D and Matsumoto T: Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood 100: 2195-2202, 2002.
-
Abe M, Hiura K, Wilde J, Moriyama k, Hashimoto T, Ozaki S, Wakatsuki S, Kosaka M, Kido S, Inoue D and Matsumoto T: Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood 100: 2195-2202, 2002.
-
-
-
-
4
-
-
0035949510
-
Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression
-
Pearse RN, Sordillo EM, Yaccoby S, Wong BR, Liau DF, Colman N, Michaeli J, Epstein J and Choi Y: Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci USA 98: 11581-11586, 2001.
-
(2001)
Proc Natl Acad Sci USA
, vol.98
, pp. 11581-11586
-
-
Pearse, R.N.1
Sordillo, E.M.2
Yaccoby, S.3
Wong, B.R.4
Liau, D.F.5
Colman, N.6
Michaeli, J.7
Epstein, J.8
Choi, Y.9
-
5
-
-
0037443533
-
RANK ligand and osteoprotegerin in myeloma bone disease
-
Sezer O, Heider U, Zavrski I, Kuhne CA and Hofbauer LC: RANK ligand and osteoprotegerin in myeloma bone disease. Blood 101: 2094-2098, 2003.
-
(2003)
Blood
, vol.101
, pp. 2094-2098
-
-
Sezer, O.1
Heider, U.2
Zavrski, I.3
Kuhne, C.A.4
Hofbauer, L.C.5
-
6
-
-
0346363760
-
The role of Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma
-
Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B and Shaughnessy JD: The role of Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349: 2483-2494, 2003.
-
(2003)
N Engl J Med
, vol.349
, pp. 2483-2494
-
-
Tian, E.1
Zhan, F.2
Walker, R.3
Rasmussen, E.4
Ma, Y.5
Barlogie, B.6
Shaughnessy, J.D.7
-
7
-
-
27644473781
-
Myeloma cells suppress bone formation by secreting a soluble Wnt idnhibitor, sFRP-2
-
Oshima T, Abe M, Asano J, Hara T, Kitazoe K, Sekimoto E, Tanaka Y, Shibata H, Hashimoto T, Ozaki S, Kido S, Inoue D and Matsumoto T: Myeloma cells suppress bone formation by secreting a soluble Wnt idnhibitor, sFRP-2. Blood 106: 3160-3165, 2005.
-
(2005)
Blood
, vol.106
, pp. 3160-3165
-
-
Oshima, T.1
Abe, M.2
Asano, J.3
Hara, T.4
Kitazoe, K.5
Sekimoto, E.6
Tanaka, Y.7
Shibata, H.8
Hashimoto, T.9
Ozaki, S.10
Kido, S.11
Inoue, D.12
Matsumoto, T.13
-
8
-
-
20844451019
-
High serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in refractory multiple myeloma: Possible role of bortezomib on osteoblast differentiation
-
Shimazaki C, Uchida R, Nakano S, Namura K, Fuchida SI, Okano A, Okamoto M and Inaba T: High serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in refractory multiple myeloma: possible role of bortezomib on osteoblast differentiation. Leukemia 19: 1102-1103, 2005.
-
(2005)
Leukemia
, vol.19
, pp. 1102-1103
-
-
Shimazaki, C.1
Uchida, R.2
Nakano, S.3
Namura, K.4
Fuchida, S.I.5
Okano, A.6
Okamoto, M.7
Inaba, T.8
-
9
-
-
27744557499
-
Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma
-
Zangari M, Esseltine D, Lee CK, Barlogie B, Elice F, Burns MJ, Kang SH, Yaccoby S, Najarian K, Richardson P, Sonneveld P and Tricot G: Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol 131: 71-73, 2005.
-
(2005)
Br J Haematol
, vol.131
, pp. 71-73
-
-
Zangari, M.1
Esseltine, D.2
Lee, C.K.3
Barlogie, B.4
Elice, F.5
Burns, M.J.6
Kang, S.H.7
Yaccoby, S.8
Najarian, K.9
Richardson, P.10
Sonneveld, P.11
Tricot, G.12
-
10
-
-
0038819051
-
Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro
-
Garrett IR, Chen D, Gutierrez G, Zhao M, Escobedo A, Rossini G, Harris SE, Gallwitz W, Kim KB, Hu S, Crews CM and Mundy GR: Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest 111: 1771-1782, 2003.
-
(2003)
J Clin Invest
, vol.111
, pp. 1771-1782
-
-
Garrett, I.R.1
Chen, D.2
Gutierrez, G.3
Zhao, M.4
Escobedo, A.5
Rossini, G.6
Harris, S.E.7
Gallwitz, W.8
Kim, K.B.9
Hu, S.10
Crews, C.M.11
Mundy, G.R.12
-
11
-
-
0034651628
-
Analysis of expressed immunoglobulin heavy chain genes in familial B-CLL
-
Sakai A, Marti GE, Caporaso N, Pittaluga S, Touchman JW, Fend F and Raffeld M: Analysis of expressed immunoglobulin heavy chain genes in familial B-CLL. Blood 95: 1413-1419, 2000.
-
(2000)
Blood
, vol.95
, pp. 1413-1419
-
-
Sakai, A.1
Marti, G.E.2
Caporaso, N.3
Pittaluga, S.4
Touchman, J.W.5
Fend, F.6
Raffeld, M.7
-
12
-
-
0029803056
-
A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet
-
Ishiyama M, Tominaga H, Shiga M, Sasamoto K, Ohkura Y and Ueno K: A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet. Biol Pharm Bull 19: 1518-1520, 1996.
-
(1996)
Biol Pharm Bull
, vol.19
, pp. 1518-1520
-
-
Ishiyama, M.1
Tominaga, H.2
Shiga, M.3
Sasamoto, K.4
Ohkura, Y.5
Ueno, K.6
-
13
-
-
0034735773
-
T-cell-mediated regulation of osteoclastogenesis by signaling cross-talk between RANKL and IFN-gamma
-
Takayanagi H, Ogasawara K, Hida S, Chiba T, Murata S, Sato K, Takaoka A, Yokochi T, Oda H, Tanaka K, Nakamura K and Taniguchi T: T-cell-mediated regulation of osteoclastogenesis by signaling cross-talk between RANKL and IFN-gamma. Nature 30: 600-605, 2000.
-
(2000)
Nature
, vol.30
, pp. 600-605
-
-
Takayanagi, H.1
Ogasawara, K.2
Hida, S.3
Chiba, T.4
Murata, S.5
Sato, K.6
Takaoka, A.7
Yokochi, T.8
Oda, H.9
Tanaka, K.10
Nakamura, K.11
Taniguchi, T.12
-
14
-
-
0035300479
-
The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells
-
Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J and Anderson KC: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61: 3071-3076, 2001.
-
(2001)
Cancer Res
, vol.61
, pp. 3071-3076
-
-
Hideshima, T.1
Richardson, P.2
Chauhan, D.3
Palombella, V.J.4
Elliott, P.J.5
Adams, J.6
Anderson, K.C.7
-
15
-
-
0034331194
-
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy
-
Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai YT, Treon SP, Lin B, Schlossman RL, Richardson P, Muller G, Stirling DI and Anderson KC: Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96: 2943-2950, 2000.
-
(2000)
Blood
, vol.96
, pp. 2943-2950
-
-
Hideshima, T.1
Chauhan, D.2
Shima, Y.3
Raje, N.4
Davies, F.E.5
Tai, Y.T.6
Treon, S.P.7
Lin, B.8
Schlossman, R.L.9
Richardson, P.10
Muller, G.11
Stirling, D.I.12
Anderson, K.C.13
-
16
-
-
19944427451
-
Connective tissue growth factor (CTGF) is regulated by Wnt and bone morphogenetic proteins signaling in osteoblast differentiation of mesenchymal stem cells
-
Luo Q, Kang Q, Si W, Jiang W, Park JK, Peng Y, Li X, Luu HH, Luo J, Montag AG, Haydon RC and He TC: Connective tissue growth factor (CTGF) is regulated by Wnt and bone morphogenetic proteins signaling in osteoblast differentiation of mesenchymal stem cells. J Biol Chem 279: 55958-55968, 2004.
-
(2004)
J Biol Chem
, vol.279
, pp. 55958-55968
-
-
Luo, Q.1
Kang, Q.2
Si, W.3
Jiang, W.4
Park, J.K.5
Peng, Y.6
Li, X.7
Luu, H.H.8
Luo, J.9
Montag, A.G.10
Haydon, R.C.11
He, T.C.12
-
17
-
-
20444433230
-
Assessment of proteasome inhibition for extending remissions (APEX) investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
-
Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Bladé J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D and Anderson KC: Assessment of proteasome inhibition for extending remissions (APEX) investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352: 2487-2498, 2005.
-
(2005)
N Engl J Med
, vol.352
, pp. 2487-2498
-
-
Richardson, P.G.1
Sonneveld, P.2
Schuster, M.W.3
Irwin, D.4
Stadtmauer, E.A.5
Facon, T.6
Harousseau, J.L.7
Ben-Yehuda, D.8
Lonial, S.9
Goldschmidt, H.10
Reece, D.11
San-Miguel, J.F.12
Bladé, J.13
Boccadoro, M.14
Cavenagh, J.15
Dalton, W.S.16
Boral, A.L.17
Esseltine, D.L.18
Porter, J.B.19
Schenkein, D.20
Anderson, K.C.21
more..
-
18
-
-
33748287079
-
-
Mateos MV, Hernández JM, Hernández MT, Gutiérrez NC, Palomera L, Fuertes M, Díaz-Mediavilla J, Lahuerta JJ, De la Rubia J, Terol MJ, Sureda A, Bargay J, Ribas P, De Arriba F, Alegre A, Oriol A, Carrera D, García-Laraña J, García-Sanz R, Bladé J, Prósper, F, Mateo G, Esseltine DL, van de Velde H and San Miguel JF: Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 108: 2165-2172, 2006.
-
Mateos MV, Hernández JM, Hernández MT, Gutiérrez NC, Palomera L, Fuertes M, Díaz-Mediavilla J, Lahuerta JJ, De la Rubia J, Terol MJ, Sureda A, Bargay J, Ribas P, De Arriba F, Alegre A, Oriol A, Carrera D, García-Laraña J, García-Sanz R, Bladé J, Prósper, F, Mateo G, Esseltine DL, van de Velde H and San Miguel JF: Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 108: 2165-2172, 2006.
-
-
-
-
19
-
-
33644833147
-
Thalidomide and hematopoietic-cell transplantation for multiple myeloma
-
Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, Fassas A, Zangari M, Hollmig K, Pineda-Roman M, Lee C, Talamo G, Thertulien R, Kiwan E, Krishna S, Fox M and Crowley J: Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 354: 1021-1030, 2005.
-
(2005)
N Engl J Med
, vol.354
, pp. 1021-1030
-
-
Barlogie, B.1
Tricot, G.2
Anaissie, E.3
Shaughnessy, J.4
Rasmussen, E.5
van Rhee, F.6
Fassas, A.7
Zangari, M.8
Hollmig, K.9
Pineda-Roman, M.10
Lee, C.11
Talamo, G.12
Thertulien, R.13
Kiwan, E.14
Krishna, S.15
Fox, M.16
Crowley, J.17
-
20
-
-
33746160660
-
Proteasome inhibitor bortezomib for the treatment of multiple myeloma
-
Cavo M: Proteasome inhibitor bortezomib for the treatment of multiple myeloma. Leukemia 20: 1341-1352, 2006.
-
(2006)
Leukemia
, vol.20
, pp. 1341-1352
-
-
Cavo, M.1
-
21
-
-
33644843725
-
-
Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V, Cangialosi C, Grasso M, Rossini F, Galli M, Catalano L, Zamagni E, Petrucci MT, De Stefano V, Ceccarelli M, Ambrosini MT, Avonto I, Falco P, Ciccone G, Liberati AM, Musto P and Boccadoro M: Italian Multiple Myeloma Network, GIMEMA. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367: 825-831, 2006.
-
Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V, Cangialosi C, Grasso M, Rossini F, Galli M, Catalano L, Zamagni E, Petrucci MT, De Stefano V, Ceccarelli M, Ambrosini MT, Avonto I, Falco P, Ciccone G, Liberati AM, Musto P and Boccadoro M: Italian Multiple Myeloma Network, GIMEMA. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367: 825-831, 2006.
-
-
-
-
22
-
-
33845520806
-
Proteasome inhibitors: Antitumor effects and beyond
-
Nencioni A, Grünebach F, Patrone F, Ballestrero A and Brossart P: Proteasome inhibitors: antitumor effects and beyond. Leukemia 21: 30-36, 2007.
-
(2007)
Leukemia
, vol.21
, pp. 30-36
-
-
Nencioni, A.1
Grünebach, F.2
Patrone, F.3
Ballestrero, A.4
Brossart, P.5
-
23
-
-
34250878387
-
Incorporating bortezomib into upfront treatment for multiple myeloma: Early results of total therapy 3
-
Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M, Cottler-Fox M, Mohiuddin A, Alsayed Y, Tricot G, Bolejack V, Zangari M, Epstein J, Petty N, Steward D, Jenkins B, Gurley J, Sullivan E, Crowley J and Shaughnessy JD: Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 138: 176-185, 2007.
-
(2007)
Br J Haematol
, vol.138
, pp. 176-185
-
-
Barlogie, B.1
Anaissie, E.2
van Rhee, F.3
Haessler, J.4
Hollmig, K.5
Pineda-Roman, M.6
Cottler-Fox, M.7
Mohiuddin, A.8
Alsayed, Y.9
Tricot, G.10
Bolejack, V.11
Zangari, M.12
Epstein, J.13
Petty, N.14
Steward, D.15
Jenkins, B.16
Gurley, J.17
Sullivan, E.18
Crowley, J.19
Shaughnessy, J.D.20
more..
-
24
-
-
33845518467
-
Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials
-
Jagannath S, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Cowan JM and Anderson KC: Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 21: 151-157, 2007.
-
(2007)
Leukemia
, vol.21
, pp. 151-157
-
-
Jagannath, S.1
Richardson, P.G.2
Sonneveld, P.3
Schuster, M.W.4
Irwin, D.5
Stadtmauer, E.A.6
Facon, T.7
Harousseau, J.L.8
Cowan, J.M.9
Anderson, K.C.10
-
25
-
-
0037097595
-
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: Therapeutic implications
-
Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi NC, Treon SP and Anderson KC: Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 99: 4525-4530, 2002.
-
(2002)
Blood
, vol.99
, pp. 4525-4530
-
-
Mitsiades, N.1
Mitsiades, C.S.2
Poulaki, V.3
Chauhan, D.4
Richardson, P.G.5
Hideshima, T.6
Munshi, N.C.7
Treon, S.P.8
Anderson, K.C.9
-
26
-
-
0036839013
-
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
-
Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F, LeBlanc R, Catley LP, Doss D, Kelly K, McKenney M, Mechlowicz J, Freeman A, Deocampo R, Rich R, Ryoo JJ, Chauhan D, Balinski K, Zeldis J and Anderson KC: Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100: 3063-3067, 2002.
-
(2002)
Blood
, vol.100
, pp. 3063-3067
-
-
Richardson, P.G.1
Schlossman, R.L.2
Weller, E.3
Hideshima, T.4
Mitsiades, C.5
Davies, F.6
LeBlanc, R.7
Catley, L.P.8
Doss, D.9
Kelly, K.10
McKenney, M.11
Mechlowicz, J.12
Freeman, A.13
Deocampo, R.14
Rich, R.15
Ryoo, J.J.16
Chauhan, D.17
Balinski, K.18
Zeldis, J.19
Anderson, K.C.20
more..
-
27
-
-
27644591608
-
Properties of thalidomide and its analogues: Implications for anticancer therapy. The AAPS J
-
Teo SK: Properties of thalidomide and its analogues: implications for anticancer therapy. The AAPS J 7: E14-E19, 2005.
-
(2005)
, vol.7
-
-
Teo, S.K.1
-
28
-
-
33746786028
-
Bortezomib increases osteoblasts activity in myeloma patients irrespective of response to treatment
-
Heider U, Kaiser M, Muller C, Jakob C, Zavrski I, Schulz CO, Fleissner C, Hecht M and Sezer O: Bortezomib increases osteoblasts activity in myeloma patients irrespective of response to treatment. Eur J Haematol 77: 233-238, 2006.
-
(2006)
Eur J Haematol
, vol.77
, pp. 233-238
-
-
Heider, U.1
Kaiser, M.2
Muller, C.3
Jakob, C.4
Zavrski, I.5
Schulz, C.O.6
Fleissner, C.7
Hecht, M.8
Sezer, O.9
-
29
-
-
34548133601
-
Bortezomib inhibits human osteoclastogenesis
-
Von Metzler I, Krebbel H, Hecht M, Manz RA, Fleissner C, Mieth M, Kaiser M, Jakob C, Sterz J, Kleeberg L, Heider U and Sezer O: Bortezomib inhibits human osteoclastogenesis. Leukemia 21: 2025-2034, 2007.
-
(2007)
Leukemia
, vol.21
, pp. 2025-2034
-
-
Von Metzler, I.1
Krebbel, H.2
Hecht, M.3
Manz, R.A.4
Fleissner, C.5
Mieth, M.6
Kaiser, M.7
Jakob, C.8
Sterz, J.9
Kleeberg, L.10
Heider, U.11
Sezer, O.12
-
30
-
-
33645736007
-
Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1
-
Anderson G, Gries M, Kurihara N, Honjo T, Anderson J, Donnenberg V, Donnenberg A, Ghobrial I, Mapara MY, Stirling D, Roodman D and Lentzsch S: Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood 107: 3098-3105, 2006.
-
(2006)
Blood
, vol.107
, pp. 3098-3105
-
-
Anderson, G.1
Gries, M.2
Kurihara, N.3
Honjo, T.4
Anderson, J.5
Donnenberg, V.6
Donnenberg, A.7
Ghobrial, I.8
Mapara, M.Y.9
Stirling, D.10
Roodman, D.11
Lentzsch, S.12
-
31
-
-
0036884062
-
Molecular mechanisms of novel therapeutic approaches for multiple myeloma
-
Hideshima T and Anderson KC: Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev 2: 927-937, 2002.
-
(2002)
Nat Rev
, vol.2
, pp. 927-937
-
-
Hideshima, T.1
Anderson, K.C.2
-
32
-
-
34247556034
-
Bone marrow mesenchymal stem cells are abnormal in multiple myeloma
-
Corre J, Mahtouk K, Attal M, Gadelorge M, Huynh A, Henry-Cappellesso S, Danho C, Laharrague P, Klein B, Rème T and Bourin P: Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia 21: 1079-1088, 2007.
-
(2007)
Leukemia
, vol.21
, pp. 1079-1088
-
-
Corre, J.1
Mahtouk, K.2
Attal, M.3
Gadelorge, M.4
Huynh, A.5
Henry-Cappellesso, S.6
Danho, C.7
Laharrague, P.8
Klein, B.9
Rème, T.10
Bourin, P.11
-
33
-
-
33845513318
-
Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma
-
Arnulf B, Lecourt S, Soulier J, Ternaux B, Lacassagne MN, Crinquette A, Dessoly J, Sciaini AK, Benbunan M, Chomienne C, Fermand JP, Marolleau JP and Larghero J: Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. Leukemia 21: 158-163, 2007.
-
(2007)
Leukemia
, vol.21
, pp. 158-163
-
-
Arnulf, B.1
Lecourt, S.2
Soulier, J.3
Ternaux, B.4
Lacassagne, M.N.5
Crinquette, A.6
Dessoly, J.7
Sciaini, A.K.8
Benbunan, M.9
Chomienne, C.10
Fermand, J.P.11
Marolleau, J.P.12
Larghero, J.13
-
34
-
-
34347400592
-
The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients
-
Giuliani N, Morandi F, Tagliaferri S, Lazzaretti M, Bonomini S, Crugnola M, Mancini C, Martella E, Ferrari L, Tabilio A and Rizzoli V: The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 110: 334-338, 2007.
-
(2007)
Blood
, vol.110
, pp. 334-338
-
-
Giuliani, N.1
Morandi, F.2
Tagliaferri, S.3
Lazzaretti, M.4
Bonomini, S.5
Crugnola, M.6
Mancini, C.7
Martella, E.8
Ferrari, L.9
Tabilio, A.10
Rizzoli, V.11
-
35
-
-
4944230728
-
Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: A vicious cycle between bone destruction and myeloma expansion
-
Abe M, Hiura K, Wilde J, Moriyama K, Hashimoto T, Ozaki S, Wakatsuki S, Kosaka M, Kido S, Inoue D and Matsumoto T: Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood 104: 2484-2491, 2004.
-
(2004)
Blood
, vol.104
, pp. 2484-2491
-
-
Abe, M.1
Hiura, K.2
Wilde, J.3
Moriyama, K.4
Hashimoto, T.5
Ozaki, S.6
Wakatsuki, S.7
Kosaka, M.8
Kido, S.9
Inoue, D.10
Matsumoto, T.11
|